Jaguar Animal Health to Host Analyst and Investor Day on November 16, 2015 in New York City

SAN FRANCISCO–(BUSINESS WIRE)–Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”),
an animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, announced today that it will host its first Analyst and
Investor Day on Monday, November 16, 2015 in New York City.

Members of Jaguar’s management team along with third-party key opinion
leaders will host a series of presentations beginning at 1:00PM eastern.
The event, along with supporting materials, will be accessible via an
archived replay through the Jaguar investor relations website at http://investors.jaguaranimalhealth.com/.

Space for the event is limited and advanced registration is required.
Analysts and institutional investors interested in attending the event
should contact Allison Soss at asoss@kcsa.com
to register.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals. Canalevia is Jaguar’s
lead prescription drug product candidate for the treatment of various
forms of diarrhea in dogs. Neonorm Calf is the Company’s
lead non-drug product. Canalevia is a canine-specific formulation of
crofelemer, an active pharmaceutical ingredient isolated and purified
from the Croton lechleri tree, which is sustainably harvested.
Neonorm is a standardized botanical extract derived from the Croton
lechleri
tree. Canalevia and Neonorm are distinct
products that act at the same last step in a physiological pathway
generally present in mammals. Jaguar has filed nine Investigational New
Animal Drug applications, or INADs, with the U.S. FDA and intends to
develop species-specific formulations of Neonorm in six
additional target species, and formulations of Canalevia for cats,
horses and dogs.

For more information, please visit www.jaguaranimalhealth.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding Jaguar’s intention to
develop species-specific formulations of Neonorm in six
additional target species, and Jaguar’s planned development of
formulations of Canalevia for cats, horses, and dogs. In
some cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms or
other similar expressions. The forward-looking statements in this
release are only predictions. Jaguar has based these forward-looking
statements largely on its current expectations and projections about
future events. These forward-looking statements speak only as of the
date of this release and are subject to a number of risks, uncertainties
and assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguar’s control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of any
new information, future events, changed circumstances or otherwise.

Jaguar-JAGX

Contacts

KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
or
Allison
Soss, 212-896-1267
asoss@kcsa.com